Aura Biosciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Income | Equity | |
| Balance, December 31, 2024 | 49,998,279 | $— | $525,934 | $(374,227) | $263 | $151,970 |
| Stock-based compensation expense | — | — | 3,514 | — | — | 3,514 |
| Employee Stock Purchase Plan issuance | 15,263 | — | 96 | — | — | 96 |
| Vesting of restricted stock | 211,770 | — | — | — | — | — |
| Unrealized loss on marketable securities | — | — | — | — | (137) | (137) |
| Currency translation adjustment | — | — | — | — | (21) | (21) |
| Other | — | — | 27 | — | — | 27 |
| Net loss | — | — | — | (27,483) | — | (27,483) |
| Balance, March 31, 2025 | 50,225,312 | $— | $529,571 | $(401,710) | $105 | $127,966 |
| Stock-based compensation expense | — | — | 3,833 | — | — | 3,833 |
| Stock option exercises | 1,424 | — | 2 | — | — | 2 |
| Vesting of restricted stock | 108,749 | — | — | — | — | — |
| Unrealized loss on marketable securities | — | — | — | — | (88) | (88) |
| Issuance of common stock through follow-on offering, net of issuance costs of $384 | 11,735,565 | — | 46,517 | — | — | 46,517 |
| Issuance of pre-funded warrants through follow-on offering, net of issuance costs of $117 | — | — | 14,156 | — | — | 14,156 |
| Issuance of common stock warrants through follow-on offering, net of issuance costs of $76 | — | — | 9,254 | — | — | 9,254 |
| Currency translation adjustment | — | — | — | — | 8 | 8 |
| Net loss | — | — | — | (27,019) | — | (27,019) |
| Balance, June 30, 2025 | 62,071,050 | — | 603,333 | (428,729) | 25 | 174,629 |
| Additional · Accumulated · Total | ||||||
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance, December 31, 2023 | 49,350,788 | $— | $512,617 | $(287,308) | $539 | $225,848 |
| Stock-based compensation expense | — | — | 2,909 | — | — | 2,909 |
| Employee Stock Purchase Plan issuance | 12,314 | — | 95 | — | — | 95 |
| Stock option exercises | 51,180 | — | 158 | — | — | 158 |
| Vesting of restricted stock | 90,123 | — | — | — | — | — |
| Unrealized loss on marketable securities | — | — | — | — | (521) | (521) |
| Net loss | — | — | — | (19,706) | — | (19,706) |
| Balance, March 31, 2024 | 49,504,405 | $— | $515,779 | $(307,014) | $18 | $208,783 |
| Stock-based compensation expense | — | — | 3,126 | — | — | 3,126 |
| Stock option exercises | 24,245 | — | 83 | — | — | 83 |
| Vesting of restricted stock | 54,708 | — | — | — | — | — |
| Unrealized loss on marketable securities | — | — | — | — | (201) | (201) |
| Net loss | — | — | — | (20,337) | — | (20,337) |
| Balance, June 30, 2024 | 49,583,358 | — | 518,988 | (327,351) | (183) | 191,454 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.